Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;65(2):543-550.
doi: 10.1007/s12026-016-8892-9.

Dyslipidemia in systemic lupus erythematosus

Affiliations
Review

Dyslipidemia in systemic lupus erythematosus

Melinda Zsuzsanna Szabó et al. Immunol Res. 2017 Apr.

Abstract

Cardiovascular disease is one of the major causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Accelerated atherosclerosis is related to traditional (age, hypertension, diabetes mellitus, dyslipidemia, obesity, smoking, and positive family history) and non-traditional, disease-related factors. Traditional risk factors are still more prominent in patients with lupus, as both hypertension and hypercholesterinemia were independently associated with premature atherosclerosis in several SLE cohorts. In this work, the authors summarize the epidemiology of dyslipidemia in lupus patients and review the latest results in the pathogenesis of lipid abnormalities. The prevalence of dyslipidemia, with elevations in total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein B (ApoB), and a reduction in low-density lipoprotein (LDL) levels are about 30% at the diagnosis of SLE rising to 60% after 3 years. Multiple pathogenetic mechanism is included, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can suppress HDL and increase TG, auto-antibodies can cause the injury of the endothelium, lipoprotein lipase (LPL) activity can be reduced by circulating inflammatory mediators and antibodies, and increased oxidative stress may trigger a wide range of pro-atherogenic lipid modifications. As a major risk factor, dyslipidemia should be treated aggressively to minimize the risk of atherosclerosis and cardiovascular events. Randomized controlled trials with statins are controversial in the detention of atherosclerosis progression, but can be favorable by inhibiting immune activation that is the arterial wall and by decreasing lupus activity.

Keywords: Accelerated atherosclerosis; Dyslipidemia; Reverse cholesterol transport; Systemic lupus erythematosus.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lupus. 1997;6(6):533-9 - PubMed
    1. J Clin Invest. 1995 Dec;96(6):2758-67 - PubMed
    1. Arthritis Rheum. 2012 Jan;64(1):285-96 - PubMed
    1. J Lipid Res. 1997 Nov;38(11):2173-92 - PubMed
    1. Lupus. 2011 Jan;20(1):5-13 - PubMed

MeSH terms

LinkOut - more resources